Cancer therapy trial pulled before it even started
NCT ID NCT07196111
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a new treatment called BAFFR CAR-T for people with B-cell blood cancers that came back or didn't respond to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure
- Boosting CAR t cells: could a pill make lymphoma therapy more effective?
- Military study probes Toxins' role in lymphoma
- Off-the-Shelf immune cells take on tough lymphoma